论文部分内容阅读
目的:探讨外周血肿瘤相关细胞角蛋白19片段抗原21-1(Cyfra21-1)、癌胚抗原(CEA)及C反应蛋白(CRP)联合检测对食管癌的诊断价值。方法:电化学发光免疫分析法测定278例食管癌患者与100名健康体检者外周血清的Cyfra21-1、CEA和CRP的水平,t和χ2检验进行数据统计分析。结果:食管癌组血清Cyfra21-1、CEA和CRP的水平及阳性率分别为(6.4±4.8)ng/mL与41.7%、(6.1±2.2)ng/mL与30.2%及(57.8±63.6)mg/L与53.2%,均显著高于健康对照组的(4.5±1.5)ng/mL与14.0%、(5.8±0.9)ng/mL与8.0%及(10.2±1.9)mg/L与22.0%,P<0.05。随着临床分期的递增,血清Cyfra21-1、CEA和CRP的水平和阳性率也不同程度上升。食管癌患者血清Cyfra21-1、CEA和CRP联合检测的敏感性和特异性明显高于单项检测,P<0.05。结论:联合检测食管癌血清中Cyfra21-1、CEA和CRP水平变化,对食管癌早期诊断和鉴别具有重要的临床价值。
Objective: To investigate the diagnostic value of combined detection of Cyfra21-1, CEA and CRP in peripheral blood tumor-associated cytokeratin 19 in esophageal cancer. Methods: The levels of Cyfra21-1, CEA and CRP in peripheral blood of 278 patients with esophageal cancer and 100 healthy subjects were determined by electrochemiluminescence immunoassay. Data were analyzed by t and χ2 test. Results: Serum levels of Cyfra21-1, CEA and CRP were (6.4 ± 4.8) ng / mL and 41.7% (6.1 ± 2.2) ng / mL and 30.2% and (57.8 ± 63.6) mg respectively in ESCC group / L and 53.2%, respectively, were significantly higher than those in healthy controls (4.5 ± 1.5 ng / mL vs 14.0% vs 5.8 ± 0.9 ng / mL vs 8.0% vs 10.2 ± 1.9 mg / L vs 22.0% P <0.05. With the increase of clinical stage, serum Cyfra21-1, CEA and CRP levels and the positive rate also increased to varying degrees. The sensitivity and specificity of combined detection of serum Cyfra21-1, CEA and CRP in patients with esophageal cancer was significantly higher than that of single test (P <0.05). Conclusion: The combined detection of serum levels of Cyfra21-1, CEA and CRP in esophageal cancer has important clinical value in the early diagnosis and differential diagnosis of esophageal cancer.